EMA accepts Mundipharma’s application for candidiasis drug rezafungin
Despite current treatments, the mortality rate for patients with invasive candidiasis remains high
Read More
Tag: mundipharma
Invasive candidiasis treatment rezafungin wins orphan drug status
IC is a severe and life-threatening form of Candida infection
Read More
Cidara, Mundipharma team up to commercialise Rezafungin
The total transaction value could exceed $568 million.
Read More
Mundipharma picks up rights to Herceptin biosimilar Tuznue
The deals allows the firm to market and distribute the drug in selected European countries following its approval
Read More
Mundipharma launches Pelmeg biosimilar in Europe
Mundipharma has announced the launch of Pelmeg (pegfilgrastim), a biosimilar of Neulasta, following its European Commission (EC) approval in November 2018.
Read More
EU OKs Mundipharma’s Neulasta biosimilar
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
Read More
Herceptin biosimilar Herzuma launched in Europe
Mundipharma announced that its network of companies has kicked off the rollout of Celltrion’s Herceptin biosimilar Herzuma in Europe.
Read More
EU nod for opioid dependence therapy
The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.
Read More
Mundipharma bags rights to sell Janssen’s Invokana, Vokanamet
Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland.
Read More
Mundipharma to launch Mabthera biosimilar in EU markets
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.
Read More
Mundipharma bags rights to Vectura’s novel respiratory therapy
Mundipharma has signed a deal with Vectura to develop and commercialise VR2076, a novel inhaled triple therapy in development for the treatment of asthma and COPD.
Read More
MundiPharma, Orexo file Zubsolv in Europe
UK-based MundiPharma and Swedish group Orexo’s have filed opioid dependence drug Zubsolv in Europe.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
